« FDA Approvals - ArthroCare Receives FDA Clearance for Latest Vertebroplasty Innovation to Help | Main | FDA Approvals - ArthroCare Receives FDA Clearance for Latest Vertebroplasty Innovation to Help »

Implications of Sarbanes-Oxley Section 404 with Scott Taub, Acting Chief


Implications of Sarbanes-Oxley Section 404 with Scott Taub, Acting Chief Accountant, SEC (PR Web)
Scott Taub, Acting Chief Accountant, SEC discusses Compliance Strategies to Evaluate Internal Control Effectiveness and the Implications of Sarbanes-Oxley Section 404. [PRWEB Mar 31, 2006] Trackback URI: http://www.prweb.com/zingpr.php/Q3Jhcy1QaWdnLVNxdWEtTG92ZS1IYWxmLVplcm8=
 

©2006 FDA-News.com. All rights reserved.